Coherus BioSciences Stock Price, News & Analysis (NASDAQ:CHRS) $2.30 0.00 (0.00%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$2.21▼$2.3750-Day Range$1.59▼$3.9852-Week Range$1.43▼$10.99Volume2.84 million shsAverage Volume2.80 million shsMarket Capitalization$256.13 millionP/E RatioN/ADividend YieldN/APrice Target$11.89 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Coherus BioSciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside416.9% Upside$11.89 Price TargetShort InterestBearish19.48% of Shares Sold ShortDividend StrengthN/ASustainability-1.08Upright™ Environmental ScoreNews Sentiment0.08Based on 7 Articles This WeekInsider TradingSelling Shares$450,662 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.17) to ($0.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.56 out of 5 starsMedical Sector128th out of 952 stocksBiotechnology Industry3rd out of 33 stocks 4.4 Analyst's Opinion Consensus RatingCoherus BioSciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.89, Coherus BioSciences has a forecasted upside of 416.9% from its current price of $2.30.Amount of Analyst CoverageCoherus BioSciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted19.48% of the outstanding shares of Coherus BioSciences have been sold short.Short Interest Ratio / Days to CoverCoherus BioSciences has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Coherus BioSciences has recently increased by 9.32%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCoherus BioSciences does not currently pay a dividend.Dividend GrowthCoherus BioSciences does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCoherus BioSciences has received a 69.63% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Pegfilgrastim", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Coherus BioSciences is -1.08. Previous Next 2.3 News and Social Media Coverage News SentimentCoherus BioSciences has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Coherus BioSciences this week, compared to 3 articles on an average week.Search Interest21 people have searched for CHRS on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Coherus BioSciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Coherus BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $450,662.00 in company stock.Percentage Held by Insiders10.99% of the stock of Coherus BioSciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.86% of the stock of Coherus BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Coherus BioSciences are expected to grow in the coming year, from ($2.17) to ($0.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Coherus BioSciences is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Coherus BioSciences is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Coherus BioSciences Stock (NASDAQ:CHRS)Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States. It also offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; and Shanghai Junshi Biosciences Co., Ltd. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Read More CHRS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CHRS Stock News HeadlinesNovember 29, 2023 | markets.businessinsider.comBuy Rating on Coherus Biosciences Anchored by Competitive Pricing and Market Strategy for LoqtorziNovember 29, 2023 | americanbankingnews.comCoherus BioSciences (NASDAQ:CHRS) Given Buy Rating at Truist FinancialDecember 5, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 28, 2023 | markets.businessinsider.comWhat 6 Analyst Ratings Have To Say About Coherus BioSciencesNovember 28, 2023 | finance.yahoo.comCoherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical AssociationNovember 28, 2023 | benzinga.comCoherus BioSciences Stock (NASDAQ:CHRS) Earnings Dates and Earning CallsNovember 26, 2023 | americanbankingnews.comDennis M. Lanfear Sells 223,100 Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS) StockNovember 26, 2023 | americanbankingnews.comInsider Selling: Coherus BioSciences, Inc. (NASDAQ:CHRS) CEO Sells $450,662.00 in StockDecember 5, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 25, 2023 | morningstar.comCoherus BioSciences Inc CHRSNovember 17, 2023 | msn.comBaird Initiates Coverage of Coherus Biosciences (CHRS) with Outperform RecommendationNovember 17, 2023 | msn.comCoherus stock rises as Baird initiates coverage on multiple tailwindsNovember 15, 2023 | seekingalpha.comCoherus BioSciences Is A Buy On The Dip After Toripalimib ApprovalNovember 10, 2023 | finance.yahoo.comWhy Coherus BioSciences Was Plummeting This WeekNovember 9, 2023 | msn.comMaxim Group Downgrades Coherus Biosciences (CHRS)November 8, 2023 | seekingalpha.comCoherus BioSciences Non-GAAP EPS of -$0.27 misses by $0.03, revenue of $74.6M misses by $7.23MNovember 7, 2023 | marketwatch.comCoherus BioSciences Shares Hit All-Time LowNovember 7, 2023 | finance.yahoo.comCoherus BioSciences Inc (CHRS) Reports 27% Rise in Q3 2023 Net RevenueNovember 7, 2023 | insidermonkey.comCoherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2023 Earnings Call TranscriptNovember 7, 2023 | seekingalpha.comEH, HOWL and TNON among pre-market losersNovember 7, 2023 | markets.businessinsider.comWhy Alteryx Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving PremarketNovember 7, 2023 | seekingalpha.comCoherus BioSciences, Inc. (CHRS) Q3 2023 Earnings Call TranscriptNovember 7, 2023 | msn.comCoherus stock falls after guidance cutNovember 3, 2023 | benzinga.comCoherus BioSciences's Earnings: A PreviewNovember 3, 2023 | finance.yahoo.comCoherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)November 3, 2023 | finance.yahoo.comCoherus BioSciences to Participate at Upcoming November Investor ConferencesNovember 1, 2023 | finance.yahoo.comVericel Corporation (VCEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseSee More Headlines Receive CHRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2023Today12/04/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CHRS CUSIPN/A CIK1512762 Webwww.coherus.com Phone(650) 649-3530FaxN/AEmployees299Year Founded2010Price Target and Rating Average Stock Price Target$11.89 High Stock Price Target$23.00 Low Stock Price Target$6.00 Potential Upside/Downside+416.9%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-291,750,000.00 Net Margins-102.86% Pretax Margin-103.04% Return on EquityN/A Return on Assets-43.25% Debt Debt-to-Equity RatioN/A Current Ratio1.85 Quick Ratio1.58 Sales & Book Value Annual Sales$211.04 million Price / Sales1.21 Cash FlowN/A Price / Cash FlowN/A Book Value($1.77) per share Price / Book-1.30Miscellaneous Outstanding Shares111,360,000Free Float99,125,000Market Cap$256.13 million OptionableOptionable Beta0.68 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Dennis M. Lanfear (Age 68)Chairman, President & CEO Comp: $1.79MMr. McDavid Stilwell (Age 51)Chief Financial Officer Comp: $719.64kMr. Bryan J. Mcmichael (Age 45)Senior VP of Accounting, Principal Accounting Officer & Corporate Controller Mr. Richard L. HameisterChief Technical OfficerMr. Marek Ciszewski J.D.Senior Vice President of Investor RelationsCheston TurbyfillVice President of CommunicationsMs. Rebecca Sunshine (Age 60)Chief Human Resources Officer Mr. Michael ChenSenior Vice President of Commercial Analytics & TradeMr. Paul Reider (Age 54)Chief Commercial Officer Dr. Theresa M. Lavallee Ph.D. (Age 57)Chief Development Officer & Chairman of Scientific Advisory Board More ExecutivesKey CompetitorsFennec PharmaceuticalsNASDAQ:FENCMesoblastNASDAQ:MESOFate TherapeuticsNASDAQ:FATETScan TherapeuticsNASDAQ:TCRXPoseida TherapeuticsNASDAQ:PSTXView All CompetitorsInsiders & InstitutionsWellington Management Group LLPBought 14,209 shares on 12/1/2023Ownership: 0.303%Deutsche Bank AGBought 12,417 shares on 11/24/2023Ownership: 0.038%Dennis M LanfearSold 223,100 sharesTotal: $450,662.00 ($2.02/share)Walleye Capital LLCBought 21,299 shares on 11/21/2023Ownership: 0.038%Jacobs Levy Equity Management Inc.Bought 188,935 shares on 11/17/2023Ownership: 0.170%View All Insider TransactionsView All Institutional Transactions CHRS Stock Analysis - Frequently Asked Questions Should I buy or sell Coherus BioSciences stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CHRS shares. View CHRS analyst ratings or view top-rated stocks. What is Coherus BioSciences' stock price target for 2024? 7 equities research analysts have issued 1 year target prices for Coherus BioSciences' stock. Their CHRS share price targets range from $6.00 to $23.00. On average, they expect the company's share price to reach $11.89 in the next twelve months. This suggests a possible upside of 416.9% from the stock's current price. View analysts price targets for CHRS or view top-rated stocks among Wall Street analysts. How have CHRS shares performed in 2023? Coherus BioSciences' stock was trading at $7.92 at the start of the year. Since then, CHRS stock has decreased by 71.0% and is now trading at $2.30. View the best growth stocks for 2023 here. Are investors shorting Coherus BioSciences? Coherus BioSciences saw a increase in short interest in November. As of November 15th, there was short interest totaling 21,690,000 shares, an increase of 9.3% from the October 31st total of 19,840,000 shares. Based on an average daily volume of 4,280,000 shares, the short-interest ratio is currently 5.1 days. View Coherus BioSciences' Short Interest. When is Coherus BioSciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024. View our CHRS earnings forecast. How were Coherus BioSciences' earnings last quarter? Coherus BioSciences, Inc. (NASDAQ:CHRS) announced its quarterly earnings data on Monday, November, 6th. The biotechnology company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.07. The biotechnology company earned $74.57 million during the quarter, compared to the consensus estimate of $80.13 million. What ETFs hold Coherus BioSciences' stock? ETFs with the largest weight of Coherus BioSciences (NASDAQ:CHRS) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA).First Trust Innovation Leaders ETF (ILDR). What is Dennis M. Lanfear's approval rating as Coherus BioSciences' CEO? 21 employees have rated Coherus BioSciences Chief Executive Officer Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among the company's employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Coherus BioSciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX). Who are Coherus BioSciences' major shareholders? Coherus BioSciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Barclays PLC (2.51%), Peregrine Capital Management LLC (1.46%), Northern Trust Corp (0.86%), Rafferty Asset Management LLC (0.79%), Sei Investments Co. (0.75%) and Charles Schwab Investment Management Inc. (0.77%). Insiders that own company stock include Dennis M Lanfear, James Healy, Jean-Frederic Viret, Mcdavid Stilwell, Vincent R Anicetti and Vladimir Vexler. View institutional ownership trends. How do I buy shares of Coherus BioSciences? Shares of CHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. Does Coherus BioSciences have any subsidiaries? The following companies are subsidiares of Coherus BioSciences: Coherus Intermediate Corp, InteKrin, InteKrin Russia, and InteKrin Therapeutics Inc..Read More This page (NASDAQ:CHRS) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coherus BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.